J&J(US:JNJ) Xin Lang Cai Jing·2026-01-21 12:42Core Insights - Isomorphic Labs, an AI pharmaceutical company spun off from DeepMind, has announced a collaboration with Johnson & Johnson's Janssen Pharmaceuticals to combine AI design capabilities with drug development expertise [1][5] - The partnership will focus on "cross-modal, multi-target research collaboration," with Isomorphic responsible for computer predictions and design, while the U.S. team will handle experimental testing and project development [1][5] - Isomorphic has also signed significant research collaborations with Novartis and Eli Lilly, totaling over $3 billion [6] Company Developments - Isomorphic Labs was established at the end of 2021 and is based on the technology and team from the renowned AlphaFold2 [6] - The company recently raised $600 million in funding led by Thrive Capital, with participation from GV and Alphabet, aimed at supporting its AI drug design engine and advancing internal projects into clinical stages [5] - In May 2024, Isomorphic and DeepMind jointly released AlphaFold3, a revolutionary tool for predicting the structure and interactions of all life molecules, enhancing drug development capabilities [8] Future Outlook - The founder of Isomorphic, Demis Hassabis, emphasized in a recent interview that AI is the ultimate tool for scientific exploration, capable of solving complex scientific challenges, with AlphaFold's success as a testament [10] - There is optimism that AI will usher in a new golden age of scientific discovery across various fields, including materials science, physics, mathematics, and weather forecasting [10]